Cargando…
Thyroid Immune-Related Adverse Events Among Cancer Patients Treated With Combination of Anti-PD1 and Anti-CTLA4 Immune-Checkpoint Inhibitors: Clinical Course and Outcomes
Introduction: Thyroid immune-related adverse events (irAEs) have been reported to have prognostic significance among cancer patients treated with anti-PD1 and anti-PDL1 monotherapies. There are scanty data in the literature thus far about the clinical course and prognostic significance of thyroid ir...
Autores principales: | Lui, David T W, Lee, Chi Ho, Tang, Vikki, Fong, Carol H Y, Lee, Alan C H, Chiu, Joanne W Y, Leung, Roland C Y, Kwok, Gerry G W, Li, Bryan C W, Cheung, Tan To, Woo, Yu Cho, Lam, Karen S L, Yau, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090404/ http://dx.doi.org/10.1210/jendso/bvab048.1729 |
Ejemplares similares
-
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014) -
OR28-07 Increased BMI Is Associated With Anti PD-1/PD-L1-Induced Thyroid Immune-Related Adverse Events
por: Pollack, Rena, et al.
Publicado: (2020) -
SAT-411 Vitamin D Levels and Risk of Thyroid Immune Related Adverse Events in Patients on Immune Checkpoint Inhibitors
por: Newman, Samantha Kass, et al.
Publicado: (2020) -
Insights From Prospective Follow-up of Thyroid Function and Autoimmunity Among Covid-19 Survivors
por: Lui, David T W, et al.
Publicado: (2021) -
OR19-5 Dissecting Thyroidal Pathways Activated by PD-L1 Blockade Identifies New Mechanisms for Thyroiditis Triggered by Immune Checkpoint Inhibitors
por: Hou, Hanxi, et al.
Publicado: (2022)